Cargando…

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine

BACKGROUND: Insight into the effect of clozapine is limited by a lack of controlling for confounding variables in current research. Our objective was to investigate the association between clozapine prescribed at discharge, following an inpatient episode, and risk of readmission into secondary menta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kesserwani, Jad, Kadra, Giouliana, Downs, Johnny, Shetty, Hitesh, MacCabe, James H, Taylor, David, Stewart, Robert, Chang, Chin-Kuo, Hayes, Richard D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431783/ https://www.ncbi.nlm.nih.gov/pubmed/30616489 http://dx.doi.org/10.1177/0269881118817387

Ejemplares similares

Antipsychotic polypharmacy prescribing and risk of hospital readmission
por: Kadra, Giouliana, et al.
Publicado: (2017)

Predictors of long-term (≥ 6 months) antipsychotic polypharmacy prescribing in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2016)

Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records
por: de Freitas, Daniela Fonseca, et al.
Publicado: (2022)

Clozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study
por: Cho, J., et al.
Publicado: (2018)

Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

Predicting parkinsonism side-effects of antipsychotic polypharmacy prescribed in secondary mental healthcare
por: Kadra, Giouliana, et al.
Publicado: (2018)

Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process
por: Kadra, Giouliana, et al.
Publicado: (2015)

41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)

Use of Natural Language Processing to identify Obsessive Compulsive Symptoms in patients with schizophrenia, schizoaffective disorder or bipolar disorder
por: Chandran, David, et al.
Publicado: (2019)

Ethnic inequalities in treatment with clozapine
por: Fonseca De Freitas, D., et al.
Publicado: (2022)

A predictor model of treatment resistance in schizophrenia using data from electronic health records
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Long‐term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality
por: Kadra, G., et al.
Publicado: (2018)

Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2021)

The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders
por: Hayes, Richard D., et al.
Publicado: (2015)

S221. QUANTITATIVE SYSTEMS PHARMACOLOGY AS AN ALTERNATIVE TO CHLORPROMAZINE EQUIVALENTS: PREDICTIVE VALIDATION FROM A CRIS DATABASE EXPERIMENT
por: Geerts, Hugo, et al.
Publicado: (2018)

Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit
por: Barnes, Thomas RE, et al.
Publicado: (2022)

Reasons for discontinuing clozapine: A cohort study of patients commencing treatment
por: Legge, Sophie E., et al.
Publicado: (2016)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

Clozapine-induced agranulocytosis
por: Mijovic, Aleksandar, et al.
Publicado: (2020)

Mental healthcare utilisation by patients before and after receiving paliperidone palmitate treatment: mirror image analyses
por: Kadra-Scalzo, Giouliana, et al.
Publicado: (2022)

Clinical correlates of early onset antipsychotic treatment resistance
por: Fonseca de Freitas, Daniela, et al.
Publicado: (2022)

M212. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Griffiths, Kira, et al.
Publicado: (2020)

Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource
por: Perera, Gayan, et al.
Publicado: (2016)

S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Sendt, Kyra-Verena, et al.
Publicado: (2018)

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland
por: Ingimarsson, Oddur, et al.
Publicado: (2016)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations
por: Krivoy, Amir, et al.
Publicado: (2021)

The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study
por: Chesney, Edward, et al.
Publicado: (2021)

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study
por: Govind, Risha, et al.
Publicado: (2021)

Defining severity of personality disorder using electronic health records: short report
por: Monk-Cunliffe, Jonathan, et al.
Publicado: (2023)

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services
por: Barnes, Thomas R. E., et al.
Publicado: (2020)

Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder
por: Chou, Fabienne, et al.
Publicado: (2016)

Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: A Pilot Study
por: Benedetti, Alessandra, et al.
Publicado: (2010)

Response after Infection-Associated Rise in Clozapine Levels in Treatment-Resistant Schizoaffective Disorder
por: Grootendorst-van Mil, Nina H., et al.
Publicado: (2018)

Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
por: McQueen, Grant, et al.
Publicado: (2021)

Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder
por: Mathalon, Daniel H., et al.
Publicado: (2010)

Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
por: Archibald, Luke, et al.
Publicado: (2019)

COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
por: Govind, Risha, et al.
Publicado: (2022)

41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?
por: Bhavsar, Vishal, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_97jctkjuof5giil814v1tnluqv